Nanobiotix (NBTX) Current Deferred Revenue: 2021-2024

Historic Current Deferred Revenue for Nanobiotix (NBTX) over the last 3 years, with Dec 2024 value amounting to $19.3 million.

  • Nanobiotix's Current Deferred Revenue rose 178.12% to $40.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $40.9 million, marking a year-over-year increase of 178.12%. This contributed to the annual value of $19.3 million for FY2024, which is 1.21% down from last year.
  • Latest data reveals that Nanobiotix reported Current Deferred Revenue of $19.3 million as of FY2024, which was down 1.21% from $19.6 million recorded in FY2023.
  • Nanobiotix's 5-year Current Deferred Revenue high stood at $19.6 million for FY2023, and its period low was $19.3 million during FY2024.
  • Its 2-year average for Current Deferred Revenue is $19.5 million, with a median of $19.5 million in 2023.
  • Data for Nanobiotix's Current Deferred Revenue shows a maximum YoY decreased of 1.21% (in 2024) over the last 5 years.
  • Nanobiotix's Current Deferred Revenue (Yearly) stood at $19.5 million in 2021, then reached $19.6 million in 2023, then fell by 1.21% to $19.3 million in 2024.